USPTO rejects NIKKEN's effort to invalidate Imagenetix's patent

NewsGuard 100/100 Score

Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent. On November 27, 2013, Imagenetix requested that its case against NIKKEN be reinstated. In this suit, which was originally filed on April 29, 2011, Imagenetix seeks damages for NIKKEN's willful infringement of Imagenetix's patent.

In response to Imagenetix's lawsuit, NIKKEN sought for the USPTO to invalidate Imagenetix's patent through the agency's re-examination process. Following a patent examiner's initial determination of the patent, NIKKEN prematurely—and incorrectly—issued a press release (on January 12, 2012) stating the following: "The United States Patent Office (USPTO) re-examined Imagenetix's patent No. 5,569,676 and rendered its final decision, rejecting Imagenetix's patent claim."  Now that the USPTO has issued its final decision confirming the validity of the patent, NIKKEN has not yet issued a correcting press release notifying its distributors or others of the agency's decision.

William P. Spencer, President of Imagenetix, stated: "I am delighted that the USPTO confirmed the validity of Imagenetix's patent. We were always confident in the merits of our patent, and we will continue to actively prosecute ongoing infringement of the patent."

Source:

Imagenetix, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.